Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced ... DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked to a reduced ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

inhibitors (from 2006), sodium-glucose cotransporter-2 (SGLT2) inhibitors (from 2013), sulfonylureas, and thiazolidinediones.” Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

While Metformin continues to be the standard first-line treatment for Type-2 diabetes, newer therapies such as SGLT2 ...

Diabetes mortality declined in the U.S. by 32.1% from 2000 to 2019, with decreases in mortality observed among all racial and ...

Currently priced at Rs 60 per tablet, Empagliflozin’s generic versions will be available for as low as Rs 9-Rs 14 per tablet, significantly reducing costs for millions of patients, states the report.